Pacer Advisors
ALLO icon

Pacer Advisors’s Allogene Therapeutics ALLO Stock Holding History

Pacer Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
+5,637
New +$12.4K ﹤0.01% 2333
2024
Q3 		– Sell
-2,372
Closed -$5.53K – 2560
2024
Q2 		$5.53K Sell
2,372
-1,285
-35% -$3.79K ﹤0.01% 3627
2024
Q1 		$16.3K Buy
+3,657
New +$15.3K ﹤0.01% 3478
2021
Q2 		– Sell
-2,028
Closed -$72K – 1408
2021
Q1 		$72K Sell
2,028
-2,802
-58% -$94.5K ﹤0.01% 1358
2020
Q4 		$122K Buy
4,830
+2,318
+92% +$75.6K ﹤0.01% 1333
2020
Q3 		$95K Buy
+2,512
New +$94.7K ﹤0.01% 1254

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pacer Advisors's ALLO Position: Q2 2026 in Review

Pacer Advisors opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 5,637 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #2333 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in ALLO as recently as Q2 2024.

Pacer Advisors first reported a position in ALLO in Q3 2020 and has held it in 6 quarters since. The position peaked at $122K in Q4 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Pacer Advisors held 5,637 shares of Allogene Therapeutics worth $12K as of Q2 2026.
  • Allogene Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2333 holding.
  • Pacer Advisors first reported a position in Allogene Therapeutics in Q3 2020 and has held it in 6 quarters since.
  • Pacer Advisors's Allogene Therapeutics position peaked at $122K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.